About 89,600 results
Open links in new tab
Press Room - Sanofi US News
Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
Sanofi lifts lid on data behind tolebrutinib’s mixed MS studies
Sanofi's tolebrutinib cuts MS progression by 31% in trial
Sanofi’s eyes approval after MS therapy slows disease progression …
Sanofi's Tolebrutinib Delays Disability Progression In Patients …
Tolebrutinib: New Sanofi’s Brain-Penetrant BTK Inhibitor | Sanofi
Novel Agent First to Slow Disability in nrSPMS - Medscape
Sanofi’s Tolebrutinib Delays MS Progression in Phase III Study ...
Press Release: Tolebrutinib demonstrated a 31% delay in time ... - Sanofi